Sfoglia per Autore
Mostrati risultati da 1 a 3 di 3
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
2014 Cicero AF; Tartagni E; Ertek S.
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
2014 Cicero AF; Tartagni E; Ertek S.
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
2014 Cicero AF; Tartagni E; Ertek S.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
Nutraceuticals for metabolic syndrome management: from laboratory to benchside. | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | CURRENT VASCULAR PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
Mostrati risultati da 1 a 3 di 3
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile